利用影像生物标志物加速药物研发和临床试验。

Using imaging biomarkers to accelerate drug development and clinical trials.

作者信息

Pien Homer H, Fischman Alan J, Thrall James H, Sorensen A Gregory

机构信息

Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

出版信息

Drug Discov Today. 2005 Feb 15;10(4):259-66. doi: 10.1016/S1359-6446(04)03334-3.

DOI:10.1016/S1359-6446(04)03334-3

PMID:15708744

Abstract

There is increasing evidence that human medical imaging can help answer key questions that arise during the drug development process. Imaging modalities such as magnetic resonance imaging, computed tomography and positron emission tomography can offer significant insights into the bioactivity, pharmacokinetics and dosing of drugs, in addition to supporting registration applications. In this review, examples from oncology, neurology, psychiatry, infectious diseases and inflammatory diseases are used to illustrate the role imaging can play. We conclude with some remarks concerning new developments that will be required to significantly advance the field of pharmaco-imaging.

摘要

越来越多的证据表明，人类医学成像有助于回答药物研发过程中出现的关键问题。除了支持注册申请外，磁共振成像、计算机断层扫描和正电子发射断层扫描等成像方式还能为药物的生物活性、药代动力学和剂量提供重要见解。在本综述中，我们通过肿瘤学、神经病学、精神病学、传染病和炎症性疾病的实例来说明成像可发挥的作用。最后，我们对显著推进药物成像领域所需的新进展发表了一些看法。